We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for roflumilast cream 0.05%, a topical phosphodiesterase-4 inhibitor, for the treatment of ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – ...

Organon & Co. ($OGN) announced an update on their ongoing clinical study. Organon & Co. has initiated a Phase 3 clinical study titled A ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...

Perioral dermatitis is a common skin condition. I share how I finally managed my flare-ups with the help of dermatologists ...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...